High Erythropoiesis Resistance Index Is a Significant Predictor of Cardiovascular and All-Cause Mortality in Chinese Maintenance Hemodialysis Patients

Xiangxue Lu, Jialing Zhang, Shixiang Wang, Qian Yu, and Han Li

Department of Blood Puriﬁcation, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

Correspondence should be addressed to Han Li; hanli@ccmu.edu.cn

Received 20 June 2020; Revised 25 September 2020; Accepted 12 November 2020; Published 26 November 2020

Academic Editor: Carla Pagliari

Copyright © 2020 Xiangxue Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Renal anemia is a common complication of hemodialysis patients. Erythropoietin (EPO) hyporesponsiveness has been recognized as an important factor to poor efficacy of recombinant human erythropoietin in the treatment of renal anemia. More importantly, increased erythropoiesis resistance index (ERI) may be associated with inflammation and increased mortality.

Objective. The objective of this research was to investigate correlated factors of EPO responsiveness and to clarify the relationships between EPO hyporesponsiveness and cardiovascular mortality and all-cause mortality among maintenance hemodialysis patients.

Methods. This prospective cohort study enrolled 276 maintenance hemodialysis patients for a 55-month follow-up to investigate the factors related to ERI and its relationship to all-cause mortality and cardiovascular mortality.

Results. ERI was positively correlated with predialysis serum high-sensitivity C-reactive protein \( (r = 0.234, p < 0.001) \), alkaline phosphatase \( (r = 0.134, p = 0.028) \), and ferritin \( (r = 0.155, p = 0.010) \) and negatively correlated with albumin \( (r = -0.206, p < 0.001) \) and creatinine \( (r = -0.232, p < 0.001) \). As multiple linear regression showed, predialysis serum albumin, high-sensitivity C-reactive protein, ferritin, and creatinine were independent correlated factors of ERI \( (p < 0.05) \). Kaplan–Meier curves showed that the cumulative incidences of both cardiovascular mortality and all-cause mortality were significantly higher in patients with \( ERI > 11.04 \text{IU/kg/w/g/dL} \) (both \( p < 0.01 \)). The high ERI group was significantly associated with higher risk for all-cause mortality \( (OR 1.781, 95\% \text{ CI 1.091 to 2.910}, p = 0.021) \) and cardiovascular mortality \( (OR 1.972, 95\% \text{ CI 1.139 to 3.417}, p = 0.015) \) after adjusting for confounders.

Conclusions. Predialysis serum albumin, high-sensitivity C-reactive protein, ferritin, and creatinine were independent correlated factors of EPO responsiveness among maintenance hemodialysis patients. Patients with higher ERI values had a higher all-cause mortality rate and cardiovascular mortality rate.

1. Introduction

Renal anemia is a common complication of chronic kidney disease (CKD). The incidence and severity of anemia increase with the decline of renal function, and more than 90% of patients with end-stage renal disease have been diagnosed with anemia [1]. It not only affects the quality of life but also increases cardiovascular events and all-cause mortality [2, 3]. The main causes of anemia in maintenance hemodialysis (MHD) patients are erythropoietin and iron deficiency [4].

The application of erythropoiesis-stimulating agents (ESAs) such as recombinant human erythropoietin (rHuEPO) has dramatically improved the management of anemia in MHD patients. But a proportion of patients do not respond well to erythropoietin, which is called erythropoietin (EPO) hyporesponsiveness or EPO resistance [5]. EPO hyporesponsiveness/resistance is a term to describe the failure to reach the targeted hemoglobin level despite higher than usual doses of EPO or a continuous need for higher EPO doses to maintain achieved hemoglobin level.

[6] Erythropoiesis resistance index (ERI) is an important evaluation index to evaluate the EPO responsiveness which is calculated by the dose of EPO and the level of hemoglobin.

Studies have shown that many factors may be associated with EPO responsiveness such as serum albumin level, inflammatory response, secondary hyperparathyroidism,
and iron deficiency [7]. In a metaregression analysis, higher doses of EPO were found to be associated with increased rate of hypertension, stroke, and thrombotic events in CKD patients [8]. Chung et al. [9] demonstrated that in MHD patients, EPO resistance was associated with left ventricular mass index, left ventricular systolic function, and cardiovascular (CV) events. It was also found that EPO hyporesponsiveness could be a predictor of all-cause mortality in MHD patients [10].

But it is still not clear whether there are other factors associated with EPO hyporesponsiveness, and the association between all-cause mortality and cardiovascular mortality should be further confirmed. Therefore, we performed this study to examine the factors associated with EPO hyporesponsiveness in MHD patients and to clarify the relationships between EPO hyporesponsiveness and cardiovascular mortality and all-cause mortality in MHD patients.

2. Subjects and Methods

2.1. Patients and Study Design. A total of 276 maintenance hemodialysis patients in December 2015 in the Department of Blood Purification, Beijing Chao-Yang Hospital, Capital Medical University, were included in this prospective cohort study. The inclusion criteria were as follows: (1) age > 18 years, (2) hemodialysis treatment duration > 3 months and in stable condition, (3) use of arteriovenous fistula, and (4) anuria. The exclusion criteria were as follows: (1) severe cardiovascular or cerebrovascular diseases, (2) infectious diseases within one month, (3) active liver diseases or cancer, (4) recent blood transfusion or surgical procedures, (5) active infectious diseases within one month, and (6) no treatment with rHuEPO, and (7) limb deficiency.

All patients received hemodialysis 3 times per week for 4 hours each time, using sugar-free bicarbonate dialysates and heparin anticoagulants during hemodialysis. The dialysate flow was 500 mL/min, and the blood flow was 200–350 mL/min. The dialysate ingredients were as follows: sodium 140 mmol/L, potassium 2.0 mmol/L, calcium 1.25 mmol/L, and magnesium 0.5 mmol/L. All patients had Kt/V > 1.2.

The study adhered to the Declaration of Helsinki and was approved by the Ethics Committee of Beijing Chao-Yang Hospital, Capital Medical University. The written informed consents were obtained from all participants.

2.2. Data Collection. The patients’ demographic data including age, gender, weight, duration of dialysis, the cause of end-stage renal disease, and treatment dose of rHuEPO were recorded. All laboratory indicators including predialysis serum albumin, prealbumin, creatinine, blood urea nitrogen (BUN), alkaline phosphatase (ALP), phosphorus, total calcium, high-sensitivity C-reactive protein (hs-CRP), intact parathyroid hormone (iPTH), ferritin, serum iron, total iron binding capacity, folic acid, and blood routine tests were detected before hemodialysis. The predialysis blood samples were drawn from the venous blood line in patients with arteriovenous fistula after an overnight fast of at least 12 hours.

The corrected serum calcium level was measured as follows: corrected total serum calcium level (mg/dL) = measured total calcium level (mg/dL) – serum albumin level (g/dL) + 4 mg/dL. [11] The transferrin saturation was measured as follows: transferrin saturation (%) = predialysis serum iron (μmol/L)/total serum iron binding capacity (μmol/L) × 100%. The EPO responsiveness was evaluated by ERI. ERI = total rHuEPO dose per week (IU)/body weight (kg)/hemoglobin (g/dL) [12]. All patients were divided into 2 groups by the median value of the ERI.

2.3. Outcome Data Collection. The outcomes of this study were defined as all-cause death and cardiovascular death. The subjects were followed up until May 31, 2020, for 55 months. CV death was defined as death due to ischemic heart disease, arrhythmias, sudden cardiac death, congestive heart failure, other heart disease, or cerebrovascular events.

2.4. Statistical Analysis. The SPSS 23.0 statistics package for Windows was used for statistical analysis. Normally distributed continuous variables were expressed as the mean ± SD, and Student t tests were used for comparing the mean values of the data. Nonnormally distributed variables were expressed as median (interquartile range), and the differences between the two groups were analyzed by the Mann–Whitney U test. Categorical variables were expressed in terms of frequency and percentage, and the chi-square test was used. Pearson or Spearman correlation was used to analyze the correlation between ERI and other clinical indicators. Multiple linear regression analysis was used for independent correlation factors of ERI. The Kaplan–Meier method was used with the log-rank test to evaluate the association between ERI and death. The Cox proportional hazards regression model was used to calculate an odds ratio (OR) with a 95% confidence interval (CI) for mortality risk, using the low ERI group as the reference value. p < 0.05 was considered statistically significant.

3. Results

3.1. Characteristics of the Patients. A total of 276 MHD patients were enrolled (age 58.37 ± 13.91 years), including 150 males (54.3%) and 126 females (45.7%). Duration of dialysis was 95.50 (86.75) months, and ERI was 12.57 ± 6.13 IU/kg/w/g/dL. The causes of end-stage renal disease were chronic glomerulonephritis in 118 patients (42.8%), diabetic nephropathy in 52 patients (18.8%), hypertensive nephropathy in 37 patients (13.4%), chronic interstitial nephritis in 21 patients (7.6%), and other renal diseases in 48 patients (17.4%).

3.2. Characteristics of Patients in the Low ERI Group and the High ERI Group. The median ERI value was 11.04 IU/kg/w/g/dL. All patients were divided into the low ERI group (ERI < 11.04 IU/kg/w/g/dL) and the high ERI group (ERI ≥ 11.04 IU/kg/w/g/dL) according to the median ERI value. As Table 1 revealed, age, predialysis serum hs-CRP, ALP, and ferritin in the patients of the high ERI group were higher than those of the low ERI group, while Alb, prealbumin, and creatinine were lower in the high ERI group.
comparing to the low ERI group \((p < 0.05)\). However, there was no significant difference between the two groups in duration of dialysis, TSAT, predialysis serum BUN, and predialysis serum folic acid \((p > 0.05)\).

### 3.3. Correlated Factors of ERI in MHD Patients

Pearson and Spearman correlation analyses were performed to assess the relationships between ERI and other factors. As shown in Table 2, ERI was positively correlated with predialysis serum high-sensitivity C-reactive protein \((r = 0.234, p < 0.001)\), alkaline phosphatase \((r = 0.134, p = 0.028)\), and ferritin \((r = 0.155, p = 0.010)\) and negatively correlated with albumin \((r = -0.206, p < 0.001)\) and creatinine \((r = -0.232, p < 0.001)\). However, ERI had no correlation with age or prealbumin \((p > 0.05)\).

In multiple linear regression model, predialysis serum Alb, hs-CRP, ferritin, and creatinine were independent correlated factors of ERI as shown in Table 3 \((p < 0.05)\).

### 3.4. Association of ERI with All-Cause and Cardiovascular Death in MHD Patients

By the end of the follow-up, 90 of the 276 patients died, including 68 cardiovascular deaths, 4 gastrointestinal bleeding deaths, 6 tumor deaths, and 12 deaths from other causes. When patients were divided into 2 groups according to the median ERI value (below or above the median value of 11.04), the Kaplan–Meier curves indicated that patients with higher ERI values had a higher all-cause mortality rate \((\text{log rank } = 6.719; p < 0.01)\) and a higher cardiovascular mortality rate \((\text{log rank } = 7.800; p < 0.01)\) (Figures 1(a) and 1(b)). Univariate and multivariate Cox regression analyses for mortality risk in MHD patients are shown in Table 4. In multivariate Cox regression analysis, the adjusted OR for all-cause mortality in the high ERI group was 1.781 \((95\% \text{ CI } 1.091 \text{ to } 2.910, p = 0.021)\), even after adjusting for confounders while the OR was 1.972 \((95\% \text{ CI } 1.139 \text{ to } 3.417, p = 0.015)\) for cardiovascular mortality.

---

**Table 1: Characteristics of patients in the low ERI group and the high ERI group.**

| Variables                  | Low ERI group \((n = 138)\) | High ERI group \((n = 138)\) | Statistics          | \(p \) value |
|----------------------------|-------------------------------|-------------------------------|---------------------|-------------|
| Age (years)                | 56.57 ± 13.14                 | 60.17 ± 14.46                 | -2.165              | 0.031*      |
| Sex (male)                 | 72 (52.17%)                   | 78 (56.52%)                   | 0.526               | 0.468       |
| Duration of dialysis (months) | 94.50 (80.75)                 | 96.00 (90.50)                 | -0.221              | 0.825       |
| WBC \((\times 10^9)\)      | 6.47 ± 1.94                   | 6.09 ± 1.77                   | 1.668               | 0.093       |
| NEUT (%)                   | 66.36 ± 8.27                  | 67.01 ± 8.91                  | -0.604              | 0.546       |
| Alb (g/L)                  | 39.69 ± 3.35                  | 37.49 ± 3.72                  | 5.612               | <0.001*     |
| Prealbumin (g/L)           | 0.33 ± 0.08                   | 0.31 ± 0.09                   | 2.621               | 0.009*      |
| BUN (mmol/L)               | 23.60 ± 4.71                  | 23.28 ± 5.80                  | 0.498               | 0.619       |
| hs-CRP (mmol/L)            | 2.63 (4.91)                   | 4.49 (6.69)                   | -3.061              | 0.002*      |
| iPTH (pg/mL)               | 268.00 (197.30)               | 290.65 (348.58)               | -1.186              | 0.236       |
| ALP (U/L)                  | 104.00 (45.50)                | 111.00 (43.00)                | -2.249              | 0.024*      |
| P (mmol/L)                 | 1.88 ± 0.53                   | 1.91 ± 0.58                   | -0.544              | 0.587       |
| cCa (mg/dL)                | 9.17 ± 1.07                   | 9.01 ± 0.97                   | 1.302               | 0.194       |
| cCa × P (mg^2/dL^2)        | 58.54 ± 18.06                 | 56.1 ± 17.02                  | 1.150               | 0.251       |
| sFerr (μg/L)               | 371.61 ± 112.30               | 402.43 ± 119.58               | -2.207              | 0.028*      |
| TSAT (%)                   | 31.99 ± 10.65                 | 33.02 ± 10.57                 | -0.659              | 0.511       |
| Folic acid (nmol/L)        | 24.50 (17.32)                 | 24.50 (17.80)                 | -1.037              | 0.300       |
| Creatinine (μmol/L)        | 937.45 ± 198.59               | 875.75 ± 191.84               | 2.625               | 0.009*      |
| ERI (IU/kg/w/g/dl)         | 8.37 (4.19)                   | 16.615 (6.93)                 | -14.364             | <0.001*     |

*Significant difference between the low ERI group and the high ERI group, \(p < 0.05\). WBC: white blood count; NEUT: neutrophil; Alb: predialysis serum albumin; prealbumin: predialysis serum prealbumin; BUN: predialysis blood urea nitrogen; hs-CRP: predialysis serum high-sensitivity C-reactive protein; iPTH: predialysis serum intact parathyroid hormone; ALP: predialysis serum alkaline phosphatase; P: predialysis serum phosphorus; cCa: predialysis corrected serum calcium; sFerr: predialysis serum ferritin; TSAT: predialysis transferrin saturation; folic acid: predialysis serum folic acid; creatinine: predialysis serum creatinine.

**Table 2: Correlation analysis for variables and ERI in MHD patients.**

| Variables                  | \(r \) value | \(p \) value |
|----------------------------|--------------|--------------|
| Age (years)                | 0.112        | 0.064        |
| Alb (g/L)                  | -0.206       | <0.001*      |
| hs-CRP (mmol/L)            | 0.234        | <0.001*      |
| Prealbumin (g/L)           | -0.111       | 0.066        |
| ALP (μg/L)                 | 0.134        | 0.028*       |
| sFerr (μg/L)               | 0.155        | 0.010*       |
| Creatinine (μmol/L)        | -0.232       | <0.001*      |

*The correlation was statistically significant, \(p < 0.05\). Alb: predialysis serum albumin; prealbumin: predialysis serum prealbumin; hs-CRP: predialysis serum high-sensitivity C-reactive protein; ALP: predialysis serum alkaline phosphatase; sFerr: predialysis serum ferritin; creatinine: predialysis serum creatinine.
4. Discussion

The results of this study demonstrated the relationship between comorbidity factors and erythropoietin resistance in MHD patients and its negative effect on survival. ERI was used to evaluate ESA hyporesponsiveness and regarded as a prognostic factor for mortality. Correlation analysis found that ERI had a statistically positive correlation with hs-CRP, ferritin, and ALP and a negative correlation with ALB and creatinine. We further found that elevated ERI was a significant predictor of all-cause mortality and cardiovascular mortality in MHD patients.

The pathogenesis of renal anemia is complex, and absolute or relative deficiency of endogenous EPO is the main cause of renal anemia. Renal anemia not only leads to fatigue, palpitating, and dyspnea and affects the quality of life among hemodialysis patients but is also an important sign of poor prognosis in hemodialysis patients [13, 14]. Clinically, some patients with renal anemia have poor improvement in hemoglobin level after treatment with weight-dependent rHuEPO, or the dose of rHuEPO per body weight required to maintain normal hemoglobin levels is significantly higher than that in other patients with renal anemia, which is a phenomenon known as EPO hyporesponsiveness/resistance [15]. It has been suggested that the deficiency of hemoglobin synthesis materials caused by absolute or functional iron deficiency is an important reason for the poor effect of rHuEPO in the treatment of renal anemia [16]. Meanwhile, anti-rHuEPO
antibodies were found in some patients, leading to rHuEPO-associated pure red blood cell aplastic anemia, which is also the cause of EPO hyporesponsiveness [17].

In our study, hs-CRP, a marker of inflammation, was significantly associated with ERI in both correlation analysis and multiple linear regression analysis. A previous study including continuous ambulant peritoneal dialysis (CAPD) patients also reported that CRP was the most important predictor of EPO hyporesponsiveness [18]. A low-grade inflammation was common in dialysis patients, which was due to the presence of oxidative stress, uremia toxin deposition, metabolic disorder, and other pathological states, leading to the disorder of cytokines [19]. Erythropoiesis might be blocked by inflammatory cytokines, such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). Elevated IL-6 and TNF-α levels might result in disorder of iron metabolism and iron stores in the reticuloendothelial system. Such cytokines might also damage red blood cells directly and induce apoptosis in marrow. It is important to prevent dialysates from bacterial contamination for dialysis patients. And more inflammatory mediators should be considered to jointly increase the risk of ESA resistance.

Similar to previous studies [20–22], we found that serum ferritin, a marker of iron stores, was an important cause of resistance to EPO treatment and a predictor of all-cause mortality in dialysis patients. However, the association between high ferritin and mortality was attenuated after adjustment for markers of inflammation. It was shown that ferritin might interact with inflammation to result in ESAs hyporesponsiveness by activating the NF-κB pathway [23]. However, the relationship between ferritin and ERI was still on debate while ferritin light chain might protect against endotoxemia [24]. More attention should be paid to this field.

We also found that ERI had a negative correlation with predialysis serum albumin and creatinine in our study. Albumin and creatinine were both indicators of nutrition status which was related to the development of malnutrition-inflammation-atherosclerosis (MIA) syndrome. Hypoalbuminemia was a relative predictor of ESA responsiveness and survival in hemodialysis patients [25–27], which was probably also associated with inflammatory reaction. Predialysis serum creatinine level, a potential surrogate of muscle mass, was negatively related to mortality in HD and peritoneal dialysis patients [28, 29]. Our findings indicated that nutrition supplement might be useful to improve ESA resistance.

Serum ALP was generally regarded as an indicator of renal bone disease in CKD patients accompanying hyperparathyroidism [30]. Hyperparathyroidism might affect EPO synthesis, erythrocyte survival, and bone marrow fibrosis contributing to ESA resistance [31]. However, ALP was not found to be an independent risk factor for ERI in multiple linear regression analysis in this study. Serum ALP is a relative correlated factor for serum iPTH level. But serum iPTH level was not significantly different between groups. The mean values of iPTH in the two groups were both within the targeted range recommended by Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline [32]. So the comorbidities and nutrition status should be taken into consideration. And it probably indicated the effectiveness of therapy with calcimimetics or parathyroidectomy.

Moreover, the current study demonstrated that the risk for all-cause and cardiovascular mortality was significantly different between groups. ESA resistance could be a risk factor for all-cause and cardiovascular mortality after adjusting for confounders. In the previous studies, the relationship between mortality and ERI was controversial. Some studies have shown that ESA resistance was associated with increased mortality [33, 34]. A meta-analysis containing 31 trials also reported that ESA dose might be positively associated with all-cause mortality independent of hemoglobin level. [8] However, another study including 320 HD patients suggested that low Hb levels and high-dose epoetin doses were significantly associated with mortality while ERI was not [35]. ESA doses are variable among anemic patients. Erythropoietin receptors have been found not only on human endothelial cells but also on tumor cells. Higher concentration of ESA might increase the risk for mortality. It is essential to determine an appropriate method to estimate ESA responsiveness for renal anemia management. Considering ERI was calculated based on baseline data, it might be influenced by the long-term follow-up period and inflammatory and nutritional status. According to our findings, ERI might provide significant information to help predict cardiovascular disease and all-cause mortality in MHD patients.

However, this was a nonrandomized, single-center study that included a relatively small number of patients, which is the limitation of the study.

In conclusion, ERI was positively associated with hs-CRP and ferritin, while serum ALB and creatinine protect from ESA resistance in HD patients. Furthermore, high ERI was a strong predictor for all-cause mortality and cardiovascular mortality in MHD patients.

Data Availability

Data was available on request.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Authors’ Contributions

Xiangxue Lu, Jialing Zhang, and Shixiang Wang contributed equally to this work.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81670673) and Beijing Natural Science Foundation (7182060).
References

[1] Y. Li, H. Shi, W.-M. Wang et al., "Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study," Medicine (Baltimore), vol. 95, no. 24, article e3872, 2016.

[2] M. Suzuki, Y. Hada, M. Akaishi et al., "Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease," International Heart Journal, vol. 53, no. 4, pp. 238–243, 2012.

[3] B. Hauber, J. Caloyeras, J. Posner, D. Brommage, S. Tzivelekis, and A. Pollock, "Hemodialysis patients’ preferences for the management of anemia," BMC Nephrology, vol. 18, no. 1, p. 253, 2017.

[4] A. Mikhail, C. Brown, J. A. Williams et al., "Renal association clinical practice guideline on anaemia of chronic kidney disease," BMC Nephrology, vol. 18, no. 1, p. 345, 2017.

[5] I. Y. Kim, J. H. Kim, M. J. Kim et al., "Low 1,25-dihydroxyvitamin D level is associated with erythropoietin deficiency and endogenous erythropoietin resistance in patients with chronic kidney disease," International Urology and Nephrology, vol. 50, no. 12, pp. 2255–2260, 2018.

[6] D. Marcelli, I. Bayh, J. I. Merello et al., "Dynamics of the erythropoiesis stimulating agent resistance index in incident hemodialysis and high-flux hemodialysis patients," Kidney International, vol. 90, no. 1, pp. 192–202, 2016.

[7] T. Ogawa and K. Nitta, "Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients," Contributions to Nephrology, vol. 185, pp. 76–86, 2015.

[8] I. Koulouridis, M. Alfayez, T. A. Trikalinos, E. M. Balk, and B. L. Jaber, "Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a meta-regression analysis," American Journal of Kidney Diseases, vol. 61, no. 1, pp. 44–56, 2013.

[9] S. Chung, H. C. Song, S. J. Shin et al., "Relationship between erythropoietin resistance index and left ventricular mass and function and cardiovascular events in patients on chronic hemodialysis," Hemodialysis International, vol. 16, no. 2, pp. 181–187, 2012.

[10] M. Okazaki, M. Komatsu, H. Kawaguchi, K. Tsuchiya, and K. Nitta, "Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients," Blood Purification, vol. 37, no. 2, pp. 106–112, 2014.

[11] K. Ito, D. Kabata, R. Ito et al., "Parathyroid hormone and premature thymus ageing in patients with chronic kidney disease," Scientific Reports, vol. 9, no. 1, p. 813, 2019.

[12] S. Fishbane and J. S. Berns, "Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin," Kidney International, vol. 68, no. 3, pp. 1337–1343, 2005.

[13] M. Nangaku, "Pathogenesis and treatment of anemia in chronic kidney disease," Rinsho Keiseki, vol. 58, no. 10, pp. 1860–1863, 2017.

[14] S. Fishbane and B. Spinowitz, "Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018," American Journal of Kidney Diseases, vol. 71, no. 3, pp. 423–435, 2018.

[15] O. Bamgboye, "Resistance to erythropoietin-stimulating agents: etiology, evaluation, and therapeutic considerations," Pediatric Nephrology, vol. 27, no. 2, pp. 195–205, 2012.

[16] D. Coyne, "It’s time to compare anemia management strategies in hemodialysis," Clinical Journal of the American Society of Nephrology, vol. 5, no. 4, pp. 740–742, 2010.

[17] A. V. Kharagietsingh, J. C. Korevaar, J. A. N. P. Vandenbroucke et al., "Incidence of recombinant erythropoietin (EPO) hyporesponsiveness, EPO-associated antibodies, and pure red cell aplasia in dialysis patients," Kidney International, vol. 68, no. 3, pp. 1215–1222, 2005.

[18] J. K. Kim, B. S. Park, M. J. Park et al., "The predictive parameters of erythropoietin hyporesponsiveness in patients on continuous ambulatory peritoneal dialysis," The Korean Journal of Internal Medicine, vol. 16, no. 2, pp. 110–117, 2001.

[19] M. Cozzolino, M. Mangano, A. Stucchì, P. Ciceri, F. Conte, and A. Galassi, "Cardiovascular disease in dialysis patients," Nephrol Dial Transplant, vol. 33, supplement 3, pp. iii28–iii34, 2018.

[20] F. Locatelli, S. Andrulli, B. Memoli et al., "Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients," Nephrol Dialysis, Transplantation, vol. 21, no. 4, pp. 991–998, 2006.

[21] K. Kalantar-Zadeh, G. H. Lee, J. E. Miller et al., "Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients," American Journal of Kidney Diseases, vol. 53, no. 5, pp. 823–834, 2009.

[22] A. Karabayis, H. Morgenstern, R. L. Pisoni et al., "Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study," Nephrol Dialysis, Transplantation, vol. 33, no. 12, pp. 2234–2244, 2018.

[23] S. Simmen, J. Cosin-Roger, H. Melhem et al., "Iron prevents hypoxia-associated inflammation through the regulation of nuclear factor-kb in the intestinal epithelium," Cellular and Molecular Gastroenterology and Hepatology, vol. 7, no. 2, pp. 339–355, 2019.

[24] A. Zarjou, L. M. Black, K. R. McCullough et al., "Ferritin light chain confers protection against sepsis-induced inflammation and organ injury," Frontiers in Immunology, vol. 10, p. 131, 2019.

[25] I. Gotsman, A. Shauer, D. R. Zwas, I. Tahiroglu, C. Lotan, and A. Keren, "Low serum albumin: a significant predictor of reduced survival in patients with chronic heart failure," Caspian Journal of Internal Medicine, vol. 42, no. 3, pp. 365–372, 2019.

[26] S. Antunes, "Hypoalbuminemia seems to be associated with a higher rate of hospitalization in hemodialysis patients," Jornal Brasileiro de Nefrologia, vol. 38, no. 1, pp. 70–75, 2016.

[27] L. Katalinic, V. Premuzic, N. Basic-Jukic, I. Barisic, and B. Jelakovic, "Hypoproteinaemia as a factor in assessing malnutrition and predicting survival on hemodialysis," Journal of Artificial Organs, vol. 22, no. 3, pp. 230–236, 2019.

[28] C. Walther, "Interdialytic creatinine change versus predialysis creatinine as indicators of nutritional status in maintenance hemodialysis," Nephrol Dialysis, Transplantation, vol. 27, no. 2, pp. 771–776, 2012.

[29] J. Park, R. Mehrota, C. M. Rhee et al., "Serum creatinine level, a surrogate of muscle mass, predicts mortality in peritoneal dialysis patients," Nephrol Dialysis, Transplantation, vol. 28, no. 8, pp. 2146–2155, 2013.

[30] N. S. Roetker, Y. Peng, A. Ashfaq, D. T. Gilbertson, and J. B. Wetmore, "Adherence to kidney disease: improving global outcomes mineral and bone guidelines for monitoring..."
biochemical parameters,” *American Journal of Nephrology*, vol. 49, no. 3, pp. 225–232, 2019.

[31] D. BRANCACCIO, M. COZZOLINO, and M. GALLIENI, “Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach,” *J Am Soc Nephrol*, vol. 15, no. 90010, pp. 21S–224, 2004.

[32] KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES CKD-MBD U G, “KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD),” *Kidney International Supplements*, vol. 7, no. 1, pp. 1–59, 2017.

[33] S. Fukuma, T. Yamaguchi, S. Hashimoto et al., “Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan,” *American Journal of Kidney Diseases*, vol. 59, no. 1, pp. 108–116, 2012.

[34] A. Schneider, I. Gutjahr-Lengsfeld, E. Ritz et al., “Longitudinal assessments of erythropoietin-stimulating agent responsiveness and the association with specific clinical outcomes in dialysis patients,” *Nephron. Clinical Practice*, vol. 128, no. 1-2, pp. 147–152, 2014.

[35] T. Ogawa, H. Shimizu, A. Kyono et al., “Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study,” *International Urology and Nephrology*, vol. 46, no. 1, pp. 151–159, 2014.